Schering-Plough has filed a New Drug Application (NDA) for a fixed-dose combination of mometasone furoate and formoterol fumarate in US, which is accepted for review by the FDA.
Tobira has reported pharmacokinetic data and results from two phase I pharmacokinetic studies for TAK-652. It is an investigational compound being developed for the treatment of HIV. Reportedly,
PSS World Medical, a distributor of medical products, has witnessed an increase of sales by 4.5% for the fiscal 2010 first quarter ended June 26, 2009. The company
CR Bard has reported an increase in net income by 44% to $112.2 million and diluted earnings per share of $1.11, an increase of 46%, for the second
Bayer HealthCare and Onyx Pharmaceuticals have announced the results for phase II trial in advanced metastatic breast cancer. The study met its primary endpoint of progression-free survival. It
Alcon has reported global sales revenue of $1.67 billion for the second quarter of 2009, a decrease of 3.4% compared to the second quarter of 2008. Net earnings
Quigley has reported the results from its phase IIb double-blind, placebo-controlled, study of topical compound QR-333. It is intended for the treatment of symptomatic diabetic peripheral neuropathy. The
Celera has reported preliminary revenue results for the quarter ended June 27, 2009. The company expects to garner revenue for the second quarter of 2009 in the range
STAAR Surgical has been informed by the FDA Division of Bioresearch Monitoring that the restrictions of the integrity hold put in place by the FDA on August 3,
The FDA has approved Novartis’ Tekturna HCT (aliskiren and hydrochlorothiazide) tablets, as initial therapy for patients who are likely to need multiple drugs to achieve their blood pressure
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.